Abstract:BACKGROUND: In the United States, blood donor testing for hepatitis B surface antigen (HBsAg) was initiated in the early 1970s. More recently, testing for antibody to hepatitis B core antigen (anti-HBc) and hepatitis B virus (HBV) DNA have been added. The incidence of hepatitis B has been declining. This study reviews the current status of testing and questions the need for continuation of HBsAg testing.STUDY DESIGN AND METHODS: From July 2011 to June 2015, a total of 22.4 million donations were serologically tested for HBsAg and anti-HBc and for HBV-DNA by nucleic acid testing (NAT). All reactive results were evaluated and a subset of donations that were either potential NAT yield (seronegative) or serologically positive but nonreactive by HBV NAT in minipools (MPs) of 16 were further evaluated by individual donation (ID)-NAT. Samples with detectable HBV DNA were defined as actively infected and considered potentially infectious.RESULTS: Routine testing plus supplemental ID-NAT identified 2035 samples representing active infection including 1965 with anti-HBc, 1602 with HBsAg, and 1453 with HBV DNA by MP-NAT, for respective rates per hundred-thousand donations of 9.10, 8.78, 7.16, and 6.50, continuing the downward trend previously observed. There were 29 HBV DNA-yield samples (1:771,389), 35 HBsAg-yield samples (anti-HBc nonreactive), and 404 with occult hepatitis B infection. There were six samples with HBsAg and HBV DNA detectable only by ID-NAT in the absence of anti-HBc; additional testing was consistent with extremely low or negligible levels of DNA.CONCLUSIONS: Point estimates of HBV infection rates among blood donors continue to decline, as do those for incidence and residual risk. Elimination of HBsAg screening would have negligible impact, with a risk less than 1 per 4 million donations.

Hepatitis Be antigen and antibody in hepatitis B surface antigen positive blood donors.

Determination of Low Level HBsAg in Serum by Microparticle Enzyme Immunoassay.

Analysis on Clinical Features and Immunity in Chronic Hepatitis B Virus Infected Patients with Low-Level Hbsag

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

Blood donor testing for hepatitis B virus in the United States: is there a case for continuation of hepatitis B surface antigen detection?

Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti-HBs.

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Serum HBeAg and HBV DNA Levels Are Not Always Proportional and Only High Levels of HBeAg Most Likely Correlate with High Levels of HBV DNA: A Community-Based Study.

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Hepatitis B Virus Chronic Infection in Blood Donors from Asian and African High or Medium Prevalence Areas: Comparison According to Sex

Epidemiological analysis of the significance of low-positive test results for antibody to hepatitis B surface and core antigens

Prevalence of antibody to hepatitis B surface antigen among qualified blood donors in Nanjing, China

Anti-HBs Seroprevalence in Blood Donors from Tyrol, Austria

The Affinity of Anti-Hbc Antibodies in Acute and Chronic Hepatitis B Infection.

Serological detection of hepatitis B virus e antigen and TNF-α in a dialysis patient

Application of a screening test for antibody the hepatitis B core antigen.

Platelet aggregation by hepatitis B surface antigen-antibody complexes

Anti-HBe titre in patients infected with wild-type and eminus variant of hepatitis B virus

Concurrently circulating hepatitis B surface antigen and heterotypic anti-HBs antibody.

Frequency of hepatitis B virus-DNA among hepatitis B surface-Ag negative, anti-hepatitis B core antibody-positive blood donors in Yazd, Iran

Association of HLA‐DRB1 alleles with status of antibodies to hepatitis B surface and e antigen